Sort
48,018 grants matching “immunotherapy”
CAREER DEVELOPMENT IN PEDIATRIC AND MEDICAL ONCOLOGY
$434,779Fred Hutchinson Cancer Research Center · K12 · FY2002 · CA
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer
$434,773Edgar G. Engleman · Stanford University · R01 · FY2021 · CA
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer
$434,773Edgar G. Engleman · Stanford University · R01 · FY2020 · CA
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer
$434,773Edgar G. Engleman · Stanford University · R01 · FY2018 · CA
Aak1 to increase infiltration of adoptively transferred cells into solid tumors
$434,754Laura Marie Rogers · Mayo Clinic Rochester · R37 · FY2024 · CA
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
$434,700Sana D Karam · University Of Colorado Denver · R01 · FY2022 · DE
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer
$434,685Elizabeth Mittendorf · Methodist Hospital Research Institute · U54 · FY2017 · CA
TLT-1 intracellular function
$434,658A. Valance Washington · Oakland University · R15 · FY2024 · HL
Role of Myeloid And CD4+ T Immune Cells in Post-Traumatic Plasticity
$434,652Jeanne T Paz · J. David Gladstone Institutes · R01 · FY2022 · NS
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancer
$434,649Jelani Chinelo Zarif · Johns Hopkins University · R01 · FY2024 · CA
Post-transplant vaccines to enhance graft-versus-leukemia responses
$434,583Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2010 · HL
Cellular Transduction with Replication-Competent Retrovirus Vectors
$434,515Noriyuki Kasahara · University Of California Los Angeles · R01 · FY2010 · CA
Role of Toll-like Receptor 9 in Fibroblastic Reticular Cell-based Therapy for Intra-abdominal Sepsis
$434,478Meihong Deng · Feinstein Institute For Medical Research · R01 · FY2023 · AI
EASTERN COOPERATIVE ONCOLOGY GROUP CLINICAL TRIALS
$434,415Northwestern University · U10 · FY2003 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP CLINICAL TRIALS
$434,415Northwestern University · U10 · FY2002 · CA
Functional interplay between Hippo and estrogen receptor ESR1
$434,399Jing Yang · University Of California, San Diego · R01 · FY2025 · CA
Functional interplay between Hippo and estrogen receptor ESR1
$434,399Kun-Liang Guan · University Of California, San Diego · R01 · FY2022 · CA
EAMG: MIR structure and specific immunosuppressive therapy
$434,391Jon Martin Lindstrom · University Of Pennsylvania · R01 · FY2008 · NS
Targeting exosomal PDL1 to improve immunotherapy
$434,375Wei Guo · Wistar Institute · P50 · FY2021 · CA
Project 1: Evolution and Durability of allo(auto)immune B cell responses in organ transplant recipients
$434,362Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2025 · AI
Targeting PP4 to improve ovarian cancer response to immunotherapy
$434,357Marion Curtis · Mayo Clinic Arizona · R37 · FY2024 · CA
MYCN drives a druggable SUMOylation program in neuroblastoma
$434,312Anthony Charles Faber · Virginia Commonwealth University · R01 · FY2024 · CA
Role of heat shock transcription factor HSF1 in tumorigenesis
$434,268Nahid F Mivechi · Augusta University · R01 · FY2025 · CA
Engineering cellular immunotherapy to modulate immune responses in hemophilia
$434,250Valder R Arruda · Children'S Hosp Of Philadelphia · R01 · FY2017 · HL
Resource for Nonhuman Primate Immune Reagents
$434,234Francois J Villinger · University Of Louisiana At Lafayette · R24 · FY2025 · OD